PT1587821E - Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina - Google Patents

Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina Download PDF

Info

Publication number
PT1587821E
PT1587821E PT03813782T PT03813782T PT1587821E PT 1587821 E PT1587821 E PT 1587821E PT 03813782 T PT03813782 T PT 03813782T PT 03813782 T PT03813782 T PT 03813782T PT 1587821 E PT1587821 E PT 1587821E
Authority
PT
Portugal
Prior art keywords
methods
transthyretin
stabilization
transyrretine
transtyretin
Prior art date
Application number
PT03813782T
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffrey W Kelly
Evan T Powers
Hossein Razavi
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32685364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1587821(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of PT1587821E publication Critical patent/PT1587821E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT03813782T 2002-12-19 2003-12-19 Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina PT1587821E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43507902P 2002-12-19 2002-12-19
US46543503P 2003-04-24 2003-04-24

Publications (1)

Publication Number Publication Date
PT1587821E true PT1587821E (pt) 2008-09-23

Family

ID=32685364

Family Applications (2)

Application Number Title Priority Date Filing Date
PT03813782T PT1587821E (pt) 2002-12-19 2003-12-19 Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina
PT08014241T PT1988397E (pt) 2002-12-19 2003-12-19 Composições e utilizações para estabilização da transtirretina e inibição do enrolamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT08014241T PT1988397E (pt) 2002-12-19 2003-12-19 Composições e utilizações para estabilização da transtirretina e inibição do enrolamento

Country Status (20)

Country Link
US (6) US7214695B2 (enExample)
EP (3) EP1988397B8 (enExample)
JP (3) JP4665076B2 (enExample)
KR (1) KR101089904B1 (enExample)
CN (2) CN100448852C (enExample)
AT (2) ATE524741T1 (enExample)
AU (2) AU2003303196C1 (enExample)
BE (1) BE2012C008I2 (enExample)
BR (1) BRPI0317463B8 (enExample)
CA (2) CA2510455C (enExample)
CY (2) CY1108467T1 (enExample)
DE (2) DE60323155D1 (enExample)
DK (2) DK1587821T6 (enExample)
ES (3) ES2524803T3 (enExample)
FI (1) FI1587821T6 (enExample)
FR (1) FR12C0008I2 (enExample)
LU (1) LU91935I2 (enExample)
PT (2) PT1587821E (enExample)
SI (1) SI1587821T2 (enExample)
WO (1) WO2004056315A2 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (ja) * 1988-08-11 1994-12-21 日本電気株式会社 ベクトル処理装置
ATE524741T1 (de) * 2002-12-19 2011-09-15 Scripps Research Inst Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
PL2319500T3 (pl) * 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
CN1976693A (zh) * 2004-05-20 2007-06-06 斯克里普斯研究所 转甲状腺素蛋白的稳定
ATE516813T1 (de) * 2004-08-26 2011-08-15 Biocrine Ab Verfahren und verbindungen zur behandlung von diabetes
US20070037875A1 (en) * 2005-08-11 2007-02-15 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
EP2074223A4 (en) * 2006-09-15 2010-03-10 Foldrx Pharmaceuticals Inc TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS
WO2010054127A1 (en) * 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
JOP20190231A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010091253A1 (en) 2009-02-06 2010-08-12 Women & Infants' Hospital Of Rhode Island Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
WO2011131661A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
KR20140054231A (ko) * 2011-09-16 2014-05-08 화이자 인코포레이티드 트랜스티레틴 해리 억제제의 고체 형태
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9642915B2 (en) 2012-05-07 2017-05-09 Cellix Bio Private Limited Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168014A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
ES2797624T3 (es) 2012-05-23 2020-12-03 Cellix Bio Private Ltd Composición para el tratamiento de la enfermedad inflamatoria intestinal
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
KR102004059B1 (ko) * 2014-09-08 2019-07-25 화이자 인코포레이티드 6-카르복시-2-(3,5-디클로로페닐)-벤족사졸의 고체 결정형
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN107344927A (zh) 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
CN106496014A (zh) * 2016-10-17 2017-03-15 河北美星化工有限公司 一种二氟尼柳的制备方法
EP4218784A3 (en) 2017-05-22 2023-09-13 National Hellenic Research Foundation Macrocyclic modulators of disease associated protein misfolding and aggregation
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
CN108558599B (zh) * 2018-03-29 2021-01-29 浦拉司科技（上海）有限责任公司 2-联苯基甲醇的合成工艺
US12268669B2 (en) 2018-12-20 2025-04-08 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
CN113874359B (zh) * 2019-04-11 2024-07-16 Inke股份公司 用于制备1-脱氧-1-甲基氨基-d-葡萄糖醇2-(3,5-二氯苯基)-6-苯并𫫇唑羧酸盐的方法
EP3969443B1 (en) 2019-05-16 2024-11-20 Teva Pharmaceuticals International GmbH Solid state forms of tafamidis and salts thereof
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
EP4059926A4 (en) 2019-11-15 2022-12-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF
EP4077287B1 (en) * 2019-12-20 2025-11-19 Pfizer Ireland Pharmaceuticals Unlimited Company Efficient process for making 6-carboxy benzoxazole derivatives
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
EP4097092A1 (en) 2020-01-28 2022-12-07 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN112683844A (zh) * 2020-12-07 2021-04-20 东华理工大学 一种振动对吲哚美辛-糖精共晶形成影响的研究方法
CN112858690B (zh) * 2021-01-21 2023-11-10 宁波职业技术学院 一种尿白蛋白/尿肌酐复合质控品及其制备方法
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
CN113372290A (zh) * 2021-05-21 2021-09-10 遵义医科大学 一种药物Tafamidis的合成方法
CN113321627B (zh) * 2021-06-06 2022-05-24 湖南第一师范学院 一种Tafamidis衍生物及其合成方法
EP4351541A2 (en) 2021-06-08 2024-04-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
EP4433461A1 (en) 2021-11-17 2024-09-25 Teva Pharmaceuticals International GmbH Solid state form of tafamidis
CN114970600B (zh) * 2022-04-11 2024-07-26 昆明理工大学 基于粒化散布熵和优化kelm的滚动轴承故障诊断方法、装置
EP4559903A1 (en) 2022-07-22 2025-05-28 Shiratori Pharmaceutical Co., Ltd. Production method for tafamidis or salt thereof
KR20250036933A (ko) 2022-07-28 2025-03-14 화이자 인코포레이티드 타파미디스 약학 조성물
US11970468B1 (en) 2023-10-23 2024-04-30 King Faisal University 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US435079A (en) 1890-08-26 Lock-nut for axles
DE602336C (de) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
US3551433A (en) * 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) * 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) * 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (de) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
US4025636A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
DE2619547A1 (de) * 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4416892A (en) * 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
DE4011106A1 (de) * 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5254692A (en) * 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
JP3021028B2 (ja) 1990-11-19 2000-03-15 株式会社日本化学工業所 アゾール型カチオン染料
CH681806A5 (enExample) 1991-03-19 1993-05-28 Ciba Geigy Ag
JPH0517458A (ja) 1991-07-04 1993-01-26 Idemitsu Kosan Co Ltd 芳香族化合物とその製造方法
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0673050A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ヘテロ環化合物
JPH0673051A (ja) 1992-08-26 1994-03-15 Asahi Glass Co Ltd ベンズアゾール誘導体
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
JPH06239849A (ja) 1993-02-16 1994-08-30 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法及び表示装置
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP3243887B2 (ja) 1993-05-28 2002-01-07 三菱化学株式会社 有機電界発光素子
JPH0797379A (ja) 1993-09-06 1995-04-11 Canon Inc 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
US5441946A (en) * 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) * 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
JP3861930B2 (ja) 1995-12-15 2006-12-27 ソニー株式会社 金属複核錯体、その製造方法及び光学的素子
JPH09227576A (ja) 1996-02-23 1997-09-02 Sony Corp 金属複核錯体、その製造方法及び光学的素子
JP3760508B2 (ja) 1996-06-10 2006-03-29 東洋インキ製造株式会社 有機エレクトロルミネッセンス素子材料およびそれを用いた有機エレクトロルミネッセンス素子
EP0956044A4 (en) 1996-06-14 2005-01-05 Progenics Pharm Inc USES OF A CHEMOKIN RECEPTOR TO INHIBIT HIV-1 INFECTION
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
GB9725782D0 (en) * 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
ATE244241T1 (de) 1998-02-04 2003-07-15 Univ Texas Hemmung der menschlichen telomerase durch g- quadruplex interaktionverbindung
US6107491A (en) * 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) * 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
JP2000100569A (ja) 1998-09-22 2000-04-07 Toray Ind Inc 発光素子
JP2001055332A (ja) 1999-06-07 2001-02-27 Saitama Daiichi Seiyaku Kk 芳香族アミジン誘導体類含有のイオントフォレ−シス用製剤
AU6687900A (en) 1999-06-18 2001-01-09 Bayer Aktiengesellschaft Phenoxy fluoropyrimidines
JP2001064205A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 製剤組成物
JP2001064166A (ja) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd 貼付剤
WO2001012183A1 (en) * 1999-08-16 2001-02-22 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
YU68102A (sh) * 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
JP3945123B2 (ja) 2000-04-10 2007-07-18 三菱化学株式会社 有機電界発光素子
JP2001301329A (ja) 2000-04-20 2001-10-31 Mitsubishi Chemicals Corp 光学記録媒体
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
EP1334091B1 (en) 2000-08-24 2012-09-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease
CA2427750C (en) 2000-11-04 2011-01-04 Aventis Pharma Limited Substituted alkanoic acids
EP1341768A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic benzimidazole compounds
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) * 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
CN101092400A (zh) * 2001-11-16 2007-12-26 日本化学医药株式会社 黄嘌呤氧化酶抑制剂
EP1478631A1 (en) 2001-11-28 2004-11-24 AstraZeneca AB Therapeutic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
BR0215240A (pt) 2001-12-19 2004-10-26 Atherogenics Inc Derivados de calcona e seu uso no tratamento de doenças
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
NZ535603A (en) 2002-03-20 2007-10-26 Metabolex Inc Substituted phenylacetic acids
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
ATE524741T1 (de) 2002-12-19 2011-09-15 Scripps Research Inst Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
JP2006517925A (ja) 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20060293339A1 (en) 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
JP2004302049A (ja) 2003-03-31 2004-10-28 Hodogaya Chem Co Ltd 感光性樹脂組成物
WO2004092140A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
JP2006523701A (ja) 2003-04-18 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
CN1976693A (zh) * 2004-05-20 2007-06-06 斯克里普斯研究所 转甲状腺素蛋白的稳定

Also Published As

Publication number Publication date
US8168663B2 (en) 2012-05-01
ES2312857T3 (es) 2009-03-01
LU91935I2 (fr) 2012-03-26
AU2010201263A1 (en) 2010-04-22
EP1988397B1 (en) 2011-09-14
PT1988397E (pt) 2011-12-02
SI1587821T2 (sl) 2025-06-30
CN1747965A (zh) 2006-03-15
SI1587821T1 (sl) 2009-02-28
FI1587821T9 (fi) 2025-07-30
DK1587821T3 (da) 2008-11-10
CN101413143A (zh) 2009-04-22
EP1587821B3 (en) 2025-04-30
JP2013256521A (ja) 2013-12-26
EP1587821A4 (en) 2007-05-09
WO2004056315A8 (en) 2005-12-08
LU91935I9 (enExample) 2019-01-04
CN101413143B (zh) 2013-09-18
AU2003303196C1 (en) 2021-03-25
US20120065237A1 (en) 2012-03-15
US20040152140A1 (en) 2004-08-05
KR101089904B1 (ko) 2011-12-05
BRPI0317463B8 (pt) 2021-05-25
EP2325651A2 (en) 2011-05-25
AU2010201263B2 (en) 2012-12-20
US7560488B2 (en) 2009-07-14
WO2004056315A2 (en) 2004-07-08
US20140134753A1 (en) 2014-05-15
JP5756151B2 (ja) 2015-07-29
US7214695B2 (en) 2007-05-08
ATE405840T1 (de) 2008-09-15
FI1587821T6 (fi) 2025-06-17
EP1587821A2 (en) 2005-10-26
US7214696B2 (en) 2007-05-08
ES2312857T7 (en) 2025-06-13
EP1587821B9 (en) 2025-07-02
JP2010270134A (ja) 2010-12-02
ES2524803T3 (es) 2014-12-12
EP2325651B1 (en) 2014-10-08
AU2010201263A8 (en) 2013-04-18
DE60323155D1 (de) 2008-10-02
BRPI0317463B1 (pt) 2017-04-18
CY1108467T1 (el) 2014-04-09
US8653119B2 (en) 2014-02-18
AU2003303196A1 (en) 2004-07-14
FR12C0008I1 (enExample) 2012-03-30
AU2003303196B2 (en) 2010-03-25
CN100448852C (zh) 2009-01-07
CA2800237C (en) 2016-05-17
US20070078186A1 (en) 2007-04-05
EP1988397B8 (en) 2012-02-15
AU2010201263B8 (en) 2013-04-18
BR0317463A (pt) 2005-11-16
EP1988397A1 (en) 2008-11-05
CY2012005I2 (el) 2015-10-07
ATE524741T1 (de) 2011-09-15
BE2012C008I2 (enExample) 2023-03-07
CY2012005I1 (el) 2015-10-07
JP4665076B2 (ja) 2011-04-06
JP2006511612A (ja) 2006-04-06
DE122012000007I1 (de) 2012-04-12
EP1587821B1 (en) 2008-08-20
CA2800237A1 (en) 2004-07-08
FR12C0008I2 (fr) 2013-01-11
KR20050090410A (ko) 2005-09-13
CA2510455C (en) 2013-03-12
US20060057644A1 (en) 2006-03-16
ES2373639T3 (es) 2012-02-07
CA2510455A1 (en) 2004-07-08
DK1587821T6 (da) 2025-05-26
WO2004056315A3 (en) 2005-08-11
US20100120919A1 (en) 2010-05-13
EP2325651A3 (en) 2011-09-21
DK1988397T3 (da) 2011-12-12

Similar Documents

Publication Publication Date Title
PT1587821E (pt) Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
DE60238086D1 (de) Platelet adp rezeptor inhibitoren
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
DE60329326D1 (de) Tace inhibitoren
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
ATE338542T1 (de) Verwendung trifluoracetylalkyl-substituierter phenyl-, phenol- und benzoylderivate in der behandlung und/oder prophylaxe von obesitas und deren begleit- und/oder folgeerkrankungen
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE429250T1 (de) Mittel zur behandlung der allergischen kontaktdermatitis
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
SE0302253D0 (sv) Lipase-colipase inhibitor
PT1551850E (pt) 2 oxo-voruscharina e seus derivados
AR021749A1 (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas.
ECSP993087A (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas
DOP2003000766A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes